Status:
COMPLETED
Remicade Infusion Management Program
Lead Sponsor:
Janssen Inc.
Conditions:
Crohn Disease
Arthritis, Rheumatoid
Eligibility:
All Genders
Brief Summary
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R....
Eligibility Criteria
Inclusion
- Subject is a good candidate to receive infliximab as per the Product Monograph
- Subject is prescribed infliximab by an appropriate physician
- Subject receives infusion in a community infusion centre.
- Subject has signed the approved consent form.
Exclusion
- Not specified in the protocol
Key Trial Info
Start Date :
August 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
1630 Patients enrolled
Trial Details
Trial ID
NCT00723905
Start Date
August 1 2005
End Date
October 1 2012
Last Update
January 15 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal, Quebec, Canada
2
Pointe-Claire, Canada